Morepen Proposes Dividend After 23 Years, Logs Rs 1.18 Bn PAT in FY25
14 May 2025
2 Min Read
CW Team
In a landmark announcement that signals a new era of growth and financial strength, Morepen Laboratories board has proposed to declared a dividend (鈧�0.20 per share) after a gap of 23 years, marking a defining moment in the company鈥檚 four-decade legacy, subject to approval of the shareholders in the forthcoming Annual General Meeting.
The declaration comes on the back of excellent financial results for FY25, with gross revenue rising to Rs 18.30 billion, up from Rs 17.04 billion in FY24 鈥� a 7.4 per cent year-on-year increase. EBITDA surged 11.5 per cent to Rs 1.92 billion, and Profit After Tax jumped to Rs 1.18 billion, while Earnings Per Share (EPS) climbed to Rs 2.20, up 17 per cent from the previous year.
Sushil Suri, Chairman & Managing Director of Morepen Laboratories, said: 鈥淭his moment is symbolic 鈥� it鈥檚 not just about distributing profits; it鈥檚 about rewarding trust. We always believe in the 鈥淛oy of Growing Together鈥�. Declaring a dividend after 23 years reflects our financial strength, operational excellence, and long-term vision of sharing and caring. Our shareholders have stood by us, and it鈥檚 time we give back.鈥�
Morepen鈥檚 API business continued to dominate, contributing Rs 9.89 billion, while the Medical Devices segment surged to Rs 4.96 billion, growing 12 per cent year-on-year. With 72 per cent of API revenue coming from exports across 80+ countries, Morepen is solidifying its position as a global pharmaceutical force. Investments in new product development, capacity expansion, and global regulatory approvals continue to propel the business forward.
Morepen Laboratories Ltd. is a vertically integrated, innovation-led pharmaceutical and healthcare company delivering high- quality APIs, branded generics, medical devices, and consumer wellness products to over 80 countries worldwide. With an installed API capacity of 514 KL, a 14 million-strong glucometer user base, and a rapidly expanding digital footprint, Morepen stands at the forefront of India's health-tech evolution. Backed by decades of trust, regulatory approvals from USFDA, WHO, and EU bodies, and a passion for innovation, Morepen is committed to making quality healthcare accessible, affordable, and future-ready.
In a landmark announcement that signals a new era of growth and financial strength, Morepen Laboratories board has proposed to declared a dividend (鈧�0.20 per share) after a gap of 23 years, marking a defining moment in the company鈥檚 four-decade legacy, subject to approval of the shareholders in the forthcoming Annual General Meeting.The declaration comes on the back of excellent financial results for FY25, with gross revenue rising to Rs 18.30 billion, up from Rs 17.04 billion in FY24 鈥� a 7.4 per cent year-on-year increase. EBITDA surged 11.5 per cent to Rs 1.92 billion, and Profit After Tax jumped to Rs 1.18 billion, while Earnings Per Share (EPS) climbed to Rs 2.20, up 17 per cent from the previous year.Sushil Suri, Chairman & Managing Director of Morepen Laboratories, said: 鈥淭his moment is symbolic 鈥� it鈥檚 not just about distributing profits; it鈥檚 about rewarding trust. We always believe in the 鈥淛oy of Growing Together鈥�. Declaring a dividend after 23 years reflects our financial strength, operational excellence, and long-term vision of sharing and caring. Our shareholders have stood by us, and it鈥檚 time we give back.鈥滿orepen鈥檚 API business continued to dominate, contributing Rs 9.89 billion, while the Medical Devices segment surged to Rs 4.96 billion, growing 12 per cent year-on-year. With 72 per cent of API revenue coming from exports across 80+ countries, Morepen is solidifying its position as a global pharmaceutical force. Investments in new product development, capacity expansion, and global regulatory approvals continue to propel the business forward.Morepen Laboratories Ltd. is a vertically integrated, innovation-led pharmaceutical and healthcare company delivering high- quality APIs, branded generics, medical devices, and consumer wellness products to over 80 countries worldwide. With an installed API capacity of 514 KL, a 14 million-strong glucometer user base, and a rapidly expanding digital footprint, Morepen stands at the forefront of India's health-tech evolution. Backed by decades of trust, regulatory approvals from USFDA, WHO, and EU bodies, and a passion for innovation, Morepen is committed to making quality healthcare accessible, affordable, and future-ready.
Next Story
HCL-Foxconn to invest Rs 37 billion in chip plant near Jewar airport
The Union Cabinet has approved the establishment of a new semiconductor unit near Jewar airport in Uttar Pradesh under the India Semiconductor Mission. This sixth plant, a joint venture between HCL and Foxconn, marks further progress in India鈥檚 semiconductor journey. The project will see an investment of Rs 37 billion.The facility will produce display driver chips for mobile phones, laptops, automobiles, PCs, and other digital devices. It is designed for a monthly capacity of 20,000 wafers and an output of 36 million units.Five semiconductor units are already in advanced stages of constructi..
Next Story
Brigade acquires Velachery land for Rs 16-billion project
Brigade Enterprises has acquired a 5.41-acre land parcel on Velachery Road, Chennai, through an outright purchase for Rs 4.417 billion. Located next to Phoenix Market City, the site will be developed into a premium residential project with a gross development value of approximately Rs 16 billion and a development potential of 0.8 million square feet.The project offers strategic access to both the OMR IT Corridor and Chennai鈥檚 Central Business District, promising strong connectivity and premium lifestyle offerings. Brigade plans to create signature residences focused on aesthetics, functional..
Next Story
Liebherr marks 10,000th XPower wheel loader milestone
Liebherr-Werk Bischofshofen has rolled out its 10,000th XPower wheel loader, marking a major production milestone. The anniversary L 580 XPower model, featuring a power-split travel drive developed with ZF Friedrichshafen AG, was handed over to the BERGER Group in Passau.鈥淭he transmission from our partner ZF is a key component of the drivetrain in our XPower wheel loaders,鈥� said Gerhard Pirnbacher, Head of Quality Management at Liebherr. 鈥淲ith an impressive total of around 64 million operating hours already clocked up by XPower models, this transmission has proven its exceptional robustn..
